Tokio Marine Asset Management Co. Ltd. Has $3.39 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Tokio Marine Asset Management Co. Ltd. increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.8% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 3,227 shares of the biopharmaceutical company’s stock after acquiring an additional 206 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Regeneron Pharmaceuticals were worth $3,392,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the stock. Metis Global Partners LLC increased its stake in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Metis Global Partners LLC now owns 5,344 shares of the biopharmaceutical company’s stock worth $5,618,000 after purchasing an additional 90 shares during the period. Huntington National Bank grew its holdings in Regeneron Pharmaceuticals by 5.8% in the 3rd quarter. Huntington National Bank now owns 605 shares of the biopharmaceutical company’s stock valued at $636,000 after buying an additional 33 shares during the last quarter. Plato Investment Management Ltd lifted its holdings in shares of Regeneron Pharmaceuticals by 3.1% during the third quarter. Plato Investment Management Ltd now owns 2,617 shares of the biopharmaceutical company’s stock worth $2,748,000 after buying an additional 79 shares during the last quarter. ICICI Prudential Asset Management Co Ltd lifted its holdings in shares of Regeneron Pharmaceuticals by 18.9% during the third quarter. ICICI Prudential Asset Management Co Ltd now owns 1,415 shares of the biopharmaceutical company’s stock worth $1,488,000 after buying an additional 225 shares during the last quarter. Finally, Parametrica Management Ltd bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $1,367,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN traded down $5.65 during mid-day trading on Thursday, hitting $798.68. 61,979 shares of the stock were exchanged, compared to its average volume of 522,000. Regeneron Pharmaceuticals, Inc. has a twelve month low of $784.96 and a twelve month high of $1,211.20. The stock’s fifty day simple moving average is $1,000.06 and its two-hundred day simple moving average is $1,035.67. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The company has a market cap of $87.77 billion, a P/E ratio of 19.90, a PEG ratio of 3.10 and a beta of 0.15.

Insider Activity at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 7.48% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on REGN. Piper Sandler reduced their price target on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a report on Friday, November 1st. BMO Capital Markets reduced their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Oppenheimer decreased their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Royal Bank of Canada cut their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $1,097.14.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.